Sudarshan K Sharma MD Limted-Gynecologic Oncology — Hinsdale, Illinois

Sudarshan K Sharma MD Limted-Gynecologic Oncology is a clinical research site located in Hinsdale, Illinois, United States 60521.

Crixeo Clinical Trials Trust Score: 22/100 (FAILING). This profile has not yet been claimed by the site owner.

Sudarshan K Sharma MD Limted-Gynecologic Oncology has participated in 23 clinical trials.

Therapeutic areas: Stage I Vulvar Cancer, Stage II Vulvar Cancer, Stage III Vulvar Cancer.

Sponsors: Gynecologic Oncology Group, National Cancer Institute (NCI).

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Hinsdale

Browse all research sites in Illinois · View every site in Hinsdale

Sponsor Feasibility Report

Trust Score: 22/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Sudarshan K Sharma MD Limted-Gynecologic Oncology?

Sudarshan K Sharma MD Limted-Gynecologic Oncology has a Crixeo Trust Score of 22/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Sudarshan K Sharma MD Limted-Gynecologic Oncology conducted?

Sudarshan K Sharma MD Limted-Gynecologic Oncology has 23 clinical trials on record. Their work covers Stage I Vulvar Cancer, Stage II Vulvar Cancer, Stage III Vulvar Cancer.

Is Sudarshan K Sharma MD Limted-Gynecologic Oncology accredited by Crixeo Clinical Trials?

Sudarshan K Sharma MD Limted-Gynecologic Oncology has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Sudarshan K Sharma MD Limted-Gynecologic Oncology?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.